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a  b  s  t  r  a  c  t
We  are living  in  an  “aluminium  age”  with  increasing  bioavailability  of  the  metal  for approximately
125 years,  contributing  signiﬁcantly  to  the aluminium  body  burden  of humans.  Over  the  course  of  life,
aluminium  accumulates  and  is stored  predominantly  in  the  lungs,  bones,  liver,  kidneys  and brain.  The  tox-
icity of aluminium  in  humans  is brieﬂy  summarised,  highlighting  links  and  possible  causal  relationships
between  a high  aluminium  body  burden  and  a number  of neurological  disorders  and  disease  states.
Aluminium  salts  have  been  used  as depot-adjuvants  successfully  in  essential  prophylactic  vaccinations
for  almost  100  years,  with  a convincing  positive  beneﬁt-risk  assessment  which  remains  unchanged.
However, allergen-speciﬁc  immunotherapy  commonly  consists  of  administering  a long-course  pro-
gramme  of  subcutaneous  injections  using  preparations  of  relevant  allergens.  Regulatory  authorities
currently  set  aluminium  limits  for  vaccines  per dose,  rather  than  per treatment  course.  Unlike  prophylac-
tic vaccinations,  numerous  injections  with  higher  proportions  of  aluminium-adjuvant  per  injection  are
applied  in  subcutaneous  immunotherapy  (SCIT)  and will signiﬁcantly  contribute  to  a higher  cumulative
life  dose  of aluminium.  While  the human  body  may  cope  robustly  with  a  daily  aluminium  overload  from
the  environment,  regulatory  cumulative  threshold  values  in  immunotherapy  need  further  addressing.
Based  on the current  literature,  predisposing  an individual  to an  unusually  high  level  of aluminium,  such
as through  subcutaneous  immunotherapy,  has  the potential  to  form  focal  accumulations  in  the  body
with  the propensity  to exert  forms  of  toxicity.  Particularly  in  relation  to longer-term  health  effects,  the
safety  of  aluminium  adjuvants  in immunotherapy  remains  unchallenged  by  health  authorities  –  evoking
the  need  for  more  consideration,  guidance,  and  transparency  on what  is  known  and  not  known  about
its  safety  in  long-course  therapy  and  what  measures  can  be taken  to prevent  or minimise  its  risks.  The
possibility  of providing  an effective  means  of  measuring  aluminium  accumulation  in patients  undergoing
long-term  SCIT  treatment  as well  as  reducing  their  aluminium  body  burden  is discussed.
©  2014  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Aluminium exposure
.1. Aluminium in the environmentAluminium (Al3+) is the third most abundant element in the
arth’s crust [1,2]. In 1825, it was isolated by the Danish physicist
ans Oersted [3]. Most aluminium is stably bound as an ore in
Abbreviations: SCIT, Subcutaneous Immunotherapy; EFSA, The European Food
afety Authority; TWI, Tolerable Weekly Intake; CHMP, Committee for Medical
roducts for Human use; EMA, European Medicine Agency; PDCO, The Paediatric
ommittee; MPL, Monophosphoryl Lipid A; PEI, Paul-Ehrlich-Institut; DFG, German
esearch Foundation; WHO, World Health Organisation.
∗ Corresponding author.
E-mail address: matthew.heath@allergytherapeutics.com (M.D. Heath).
ttp://dx.doi.org/10.1016/j.vaccine.2014.05.063
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clay, minerals, rocks and gemstones. Mobilisation of aluminium
in the environment can result from natural processes (acidic
precipitation) and through anthropogenic activities. This light-
weight, non-magnetic, silvery white-coloured metal can be
produced from the aluminium ore—bauxite—by a high energy-
consuming mining process; it is this process which provides
the world its main source of the metal. As a consequence of
this technological progress, aluminium has become increasingly
bioavailable for approximately the past 125 years [2]. Toxic mine
tailings can leach and seep into aquifers, contaminating local
water sources and soils. An increased solubility by anthropogenic
pollutants such as acid rain is further contributing to this [5].
Most human exposure comes from the environment (the food
we eat and the water we drink) [4]; additionally, aluminium is
added for the coagulation of contaminants in drinking water. As
a raw material, aluminium is used extensively in industry owing
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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o its unique and inherent properties (e.g. as a soft, light weight,
esistant, non-corrosive metal). Aluminium and its compounds can
e found in drinking water, our food, air, medicines, deodorants
antiperspirants), cosmetics and forms essential components in
any household items and equipment, packaging, buildings and in
erospace engineering. It is the most widely used and distributed
etal on the planet. Consequently, the human race is commonly
eferred to as living in an “aluminium age”.
.2. Human exposure to aluminium
Food, drinking water, air and medicines are considered to be
ources of the aluminium load for humans (Fig. 1). With the
tilisation of aluminium growing, bioavailability is increasing con-
inuously. In 1950 this dietary aluminium load was  thought to be
pproximately 1 mg  per day, it is estimated to be 100 mg  in 2050 [2].
rewski et al. [4] present an overview of aluminium sources from
oodstuffs and other products which contribute to this increase in
xposure and subsequent load.
Uptake of Al3+ via the gastrointestinal tract is low: mostly
eported as being between 0.1% and 1% [6], although considerably
igher rates are described [7]. Of note, the bioavailability in drink-
ng water is co-dependent on its silicic acid content: large amounts
f silica in drinking water reduce the uptake of aluminium and
ice versa [6,8]. Furthermore, aluminium interacting with various
eptides, (glyco-) proteins and carbohydrates such as [iso-] citrate,
alate, oxalate, succinate, tartrate, etc. must be taken into account.
uch forms of aluminium signiﬁcantly increase absorption rates
6,9–11].Aluminium is excreted primarily via faeces and urine, with skin,
air, nails, sebum, semen, and sweat also having been described
s excretion routes [2]. In fact, >95% aluminium is efﬁciently elim-
nated through the kidneys which helps explain why  we can cope
ig. 1. A representation of human exposure to aluminium and its impact on the
ody [2].ne 32 (2014) 4140–4148 4141
robustly with a daily dietary aluminium overload from the environ-
ment, minimising but not completely eliminating the risk of focal
accumulations of the metal in other areas of the body. However,
dialysis patients have been shown to bear levels of >30 g/L alu-
minium in their sera, subsequently being linked with osteomalacia
and related disorders [3]. High-risk individuals such as these would
be at risk of longer-term health problems linked to aluminium
accumulation/toxicity, outlined in Section 2 of this review.
Sweating particularly appears to be an underestimated excre-
tion route for aluminium [12] that has been calling into question the
widespread use of antiperspirants, which themselves contribute to
the aluminium body burden [13,14].
Recently, the German Federal Institute for Risk Assessment
(Bundesinstitut für Risikobewertung = BfR) calculated the daily
systemic absorption of aluminium through the healthy skin to con-
stitute 10.5 g, which is above the amount considered safe for an
adult (8.6 g per day). Systemic absorption through damaged skin
(e.g. after shaving) is much higher. The BfR therefore announced
a warning not to apply an aluminium-containing antiperspirant
shortly after shaving the armpit because of the signiﬁcant contri-
bution to the general aluminium body burden [15].
1.3. Aluminium in the body
Aluminium performs no obvious biological function in the
human body and there is no evidence to date of aluminium-speciﬁc
metabolism [16]. However, aluminium will take a number of differ-
ent routes of absorption and interactions which will now be brieﬂy
summarised.
In the blood, >90% aluminium in plasma is associated with
transferrin [2], with the approximate concentration of aluminium
believed to be ∼1–2 g/L. The lungs and the bones are considered
to be the major deposits in the body. Bone, lung, muscle, liver and
brain are described as bearing approximately 60, 25, 10, 3 and
1% of the total body burden of aluminium, respectively [4]. Alu-
minium concentrations are also thought to increase with age [4].
The monocarboxylate transporter, the transferrin receptor shuttle,
aluminium citrate and, recently described, ferritin are considered to
be the transport routes of aluminium for crossing the blood–brain
barrier [5,7–9,16]. In 2001, Yokel et al. published a half-life of 150
days of aluminium in the brains of rats following a single parenteral
application of an 26aluminium isotope [17].
Monitoring aluminium accumulation in humans is challenging.
Urine and blood plasma analysis can be performed however neither
will provide an accurate indication of the total aluminium body
burden of an individual. Exley, 2013 best describes the true body
burden of aluminium: “for an individual is clearly not yet a quantity
which is accessible by conventional means, at least not for a living
person. While measurements of body burden are available these are
actually indirect estimates of the systemic body burden, for example,
the aluminium content of urine. These measurements are particularly
helpful in comparing relative changes in the body burden of aluminium
between individuals or between populations. They are, however, are
less informative about where aluminium is found in the body or its
potential for systemic toxicity” [2].
1.4. Human threshold values
EFSA (The European Food Safety Authority) stated in a recent
report [18]: “in view of the cumulative nature of aluminium in the
organism after dietary exposure, the Panel considered it more appro-
priate to establish a tolerable weekly intake (TWI) for aluminium
rather than a tolerable daily intake (TDI). . .
. . .Based on combined evidence. . . the Panel established a TWI  of
1 mg of aluminium/kg bw/week.”
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Animal studies are the rationale for the deﬁnition of this thresh-
ld value: “The available studies have a number of limitations and do
ot allow any dose-response relationships to be established. The Panel
herefore based its evaluation on the combined evidence from sev-
ral studies in mice, rats and dogs that used dietary administration of
luminium compounds.”
In conclusion, the EFSA stated: “The TWI  of 1 mg/kg bw/week is
herefore likely to be exceeded in a signiﬁcant part of the European
opulation. . ..
. . ..Cereals and cereal products, vegetables, beverages and certain
infant formulae appear to be the main contributors to the dietary
aluminium exposure.” [18]
In 2012, the WHO  (World Health Organisation) deﬁned a
PTWI = provisional tolerable weekly intake”  of 2 mg/kg body weight
s threshold and conﬁrmed in the same document that this
hreshold is also achieved by adults consuming, e.g., cereals or,
espectively, is exceeded regularly by children from the exposure
o children’s food [19].
The aluminium exposure of infants and toddlers from infant
ormulae appears to be particularly problematic. In a follow-up
nvestigation by Chuchu and co-workers [20], commercially avail-
ble formulae were again examined for aluminium. Regrettably,
o reduction was found when compared to previous examina-
ion in 2010 [21]: the current aluminium concentrations in all 30
roducts examined were higher than the concentrations recom-
ended for drinking water, 14/30 even exceeded the maximum
llowable value of 200 g/l [20]. Taking into account that at this age
he blood–brain barrier has not fully matured, this (unnecessary)
luminium exposure appears complacent.
In summary, we have been living in a world with increasing
ioavailability of aluminium for approximately 125 years, con-
ributing signiﬁcantly to the aluminium body burden of humans.
he most common route of absorption with regard to volume
s the gastrointestinal tract. Over the course of life, aluminium
ccumulates and is deposited predominantly in the lungs, bones,
iver, kidneys and brain. While the human body may  cope robustly
ith a daily aluminium overload from the environment, the reg-
latory cumulative threshold values in foods determined solely
rom animal studies are thought to be regularly exceeded. Any
ew or unnecessary additional exposures to aluminium have the
ropensity to overwhelm the body’s coping mechanisms, with the
otential to exert a form of toxicity. Of particular note are the
orms of aluminium of pathophysiologic signiﬁcance and asso-
iated longer-term health effects, which will be described and
iscussed in more detail.
. Toxicity of aluminium in humans
Paracelsus: “All things are poison, and nothing is without poi-
on; only the dose permits something not to be poisonous.”
Aluminium has very well established neurotoxic properties. The
ost up-to-date and in-depth human health risk assessment of alu-
inium was conducted by Krewski and colleagues [4], who  stated:
Modest evidence of an effect exists for reproductive toxicity following
ral exposure, for neurological toxicity following either oral or injec-
ion exposure, and for bone toxicity following injection exposure of
luminium”.
In the contemplation of toxicity, it is established practice to dis-
inguish acute from chronic forms. This classiﬁcation is reasonable
or aluminium-related toxicity as well [6,22].
.1. Acute toxicityAcute toxicity refers to harmful effects caused by high concen-
rations of aluminium. Descriptions are available particularly with
egard to dementia:ne 32 (2014) 4140–4148
2.1.1. Dialysis dementia/dialysis encephalopathy
The ﬁrst description of the aluminium-related dementias can
be traced back into the 1970s [23,24] and most studies report
a positive link between aluminium accumulation and cognitive
impairments. However, some study designs are highly variable and
their quality is questionable. More recently, evidence has demon-
strated that high aluminium exposure from, i.e., drinking water can
trigger acute episodes of dementia in patients with renal insufﬁ-
ciency, providing strong evidence for the causal relationship with
aluminium [25].
The use of silicic acid has also been suggested to have a pro-
tective affect against the development of dementia [26–28]. As
previously mentioned, the bioavailability of aluminium in drink-
ing water is, for instance, co-dependent on its silica content: large
amounts of silicic acid in drinking water reduce the uptake of alu-
minium and vice versa [6,10]. Exley and co-workers [26] have
demonstrated that regular consumption of silicon-rich mineral
waters reduce gastrointestinal uptake of aluminium and removal of
systemic aluminium from the body. As a result, this may provide the
basis of a non-invasive means for a therapy to treat the symptoms
of Alzheimer’s disease, in an attempt to reduce their body bur-
den of aluminium. However, in-depth follow up studies involved in
identifying clinical improvement of symptoms are at an early stage.
2.1.2. Aluminium powder in silicosis
In the 1940s, inhalation of aluminium was propagated as pro-
phylaxis against silicosis in mine workers [29]. Examinations of
these mine workers conducted in the study revealed the neurotoxic
effects of this aluminium exposure [30].
2.1.3. Camelford accident
In 1988, the drinking water of the Camelford community
in Cornwall, UK, was accidentally contaminated with 20 t of
aluminium sulphate. Follow-up examination in the affected
population demonstrated the consecutive neurotoxic effects of alu-
minium [31]. In another study, a neuropathological examination of
an exposed individual who  died from an unspeciﬁed neurological
condition was  performed. High aluminium levels were measured
in affected regions of the cortex, where a rare form of  amyloid
angiopathy was  identiﬁed [32].
2.2. Chronic toxicity
Chronic toxicity refers to the harmful effects of protracted low-
dose contamination.
2.2.1. Neurodegenerative effects
Increased concentrations of aluminium have been demon-
strated in senile plaques in the brains of Alzheimer patients. The
property of aluminium to produce amyloid-beta and cause damage
to neurons, as well as epidemiologic connections, have been indica-
tive of a relationship between aluminium and Alzheimer’s disease
for decades. Current reviews cite respective, but sometimes contra-
dictory, studies [33]. To summarise the current state of knowledge,
Bondy et al. [34], state “the ﬁnal scientiﬁc proof of a causal relation-
ship between aluminium and Alzheimer’s disease is still pending.
However, there is no longer any doubt about the neurotoxicity of
aluminium in neurodegenerative diseases representing the chronic
toxicity in humans”.In addition to these neurotoxic effects, a number of additional
diseases, of which will be outlined, are being associated with alu-
minium as a causal relationship. However, the degree of evidence
is somewhat weaker. Of note are:
/ Vacci
2
b
b
s
a
o
[
2
c
v
a
d
e
b
b
i
a
c
p
3
A
a
b
s
c
w
p
a
a
a
[
e
i
a
t
t
v
t
i
r
d
b
c
h
p
m
i
a
g
i
a
t
T
mM.F. Kramer, M.D. Heath 
.2.2. Benign and malign diseases of the breast
A current review summarises the evidence on the relationship
etween aluminium and both benign and malignant diseases of the
reast [14]. An increased absorption of aluminium from antiper-
pirants applied to the armpits is highlighted here. Such cutaneous
bsorption is increased by shaving the armpits, resulting in the rec-
mmendation not to apply deodorants immediately after shaving
15,35].
.2.3. Myofasciitis
In France, a form of “macrophagic myofasciitis” is being dis-
ussed in connection with aluminium-containing adjuvants used in
accinations that could trigger a cascade of immunological events
ssociated with this autoimmune condition [36–39].
Additional diseases described are: autism [40], Gulf War  Syn-
rome, allergies and other autoimmune diseases [41]. However,
vidence here is poor and frequently the discussion is characterised
y emotion.
In summary, though ﬁnal scientiﬁc proof of a causal relationship
etween aluminium and Alzheimer’s disease is still pending, there
s no doubt about the neurotoxicity of aluminium. Predisposing
n individual to an unnecessary high body burden of aluminium
an be considered a prime cause for triggering toxicity linked to
athophysiologic signiﬁcance.
. Aluminium in prophylactic vaccinations
Aluminium compounds (e.g. aluminium oxyhydroxide;
lO(OH), aluminium phosphate; AlPO4) have been used as
djuvants since 1926 [42,43], the exact mechanism of action is
rieﬂy summarised in Section 4.1.2 but it is not yet fully under-
tood [44]. The vaccine preparation is primarily micrometer-sized
lusters of nano-sized primary particles of the aluminium salt with
hich the antigen is associated with. The antigen physio-chemcial
roperties and form of aluminium will dictate the strength of
dsorption [42]. There have been very few data reporting serious
dverse reactions to aluminium in vaccines [45]. Aluminium salts
re considered to be a stimulator of the Th2 immune response
44,46–50]. In addition to its adjuvant effects, they mediate a depot
ffect resulting in the antigen to be released more slowly from the
njection site. It is inherent to this effect that aluminium salts when
pplied by the parenteral (usually intramuscular) route, stays in
he body for prolonged periods of time.
Reﬂections on toxicity have resulted in ongoing and some-
imes irrational discussion of the safety of aluminium-adjuvanted
accines [41], which has the potential to invoke misguidance in
he risk-beneﬁt evaluations of immunisation programmes. Other
nvestigations, such as Keith et al. [51], could not demonstrate a
isk for infants examined. However, it is noted that the aluminium
oses applied in vaccinations contribute to the lifelong human body
urden of aluminium [46].
Currently the authorities do not conceive that aluminium-
ontaining vaccines induce any potential (short- and/or long-term)
azards or safety issues. Since its ﬁrst discovery by the English
hysician Edward Jenner, it is estimated that approximately 9
illion lives have been saved as a consequence of vaccine immun-
sation, a signiﬁcant proportion of which contain aluminium-based
djuvants [45]. Unlike most medications, essential vaccinations are
iven prophylactically to a healthy population (frequently children)
n which the long-term beneﬁts far outweigh any proposed risks,
nd form a pivotal component in the ﬁght to eradicate disease.The dose of aluminium salt in vaccines varies depending on
he manufacturer; it could be as low as 170 g per dose in
ripedia (diptheria/tetanus) or as high as 850 g/dose in Tetra-
une (Haemophilus inﬂuenzae type b) [52]. It is important to takene 32 (2014) 4140–4148 4143
into account that the content of pure aluminium in e.g. AlO(OH)
is approximately 45% (molecular weight of AlO(OH) = 60; alu-
minium = 27). Thus, based on the manufacturer’s declaration, the
proportion of aluminium in the AlO(OH) amounts to approximately
half. Moreover, the number of prophylactic vaccinations against
infectious diseases is usually low (e.g. up to three doses). A study
by Keith et al. [51], calculated that exposure to aluminium from
vaccinations in early childhood exceeds that from dietary sources,
however, was calculated to fall below a minimal risk level set by
The Agency for Toxic Substances and Disease Registry, U.S.
The design of double blind placebo controlled (DBPC) vaccina-
tion studies use (essentially toxic) aluminium adjuvants in placebo
formulations, clearly adding unnecessarily to an individual’s alu-
minium body burden. This anomaly makes it extremely difﬁcult
to assess the safety or risks of each study appropriately [53]. Fur-
thermore, risk assessments frequently refer to the comparably,
much higher environmental exposures to aluminium. The impor-
tant differences between aluminium compounds that are applied
parenterally or via the gastrointestinal tract are often negated
[2]. This includes a difference in absorption (100% of aluminium
absorbed via the parenteral route [17] versus 0.1–3% via the gas-
trointestinal route [see above]), and a prolonged clearance of such
mediators of an aluminium depot effect is an inherent property of
aluminium salts.
Despite the positive risk–beneﬁt assessment of essential
immunisation programmes, The French National Assembly pub-
lished concerns in a summary of recommendations on vaccination,
recognising the associated risks of aluminium accumulation
and stated: “In the light of the results of some studies car-
ried out on aluminium.  . ..it is necessary to research into new,
non-neuromigrating adjuvants, which could eventually replace
aluminium. . .”  [54].
In summary, aluminium salt compounds have been used suc-
cessfully in essential vaccinations for almost 100 years, and the
positive beneﬁt-risk assessment remains unchanged. Aluminium-
containing vaccinations against infectious diseases are adjuvanted
with comparably low amounts of aluminium and are usually
applied only a few times. Nevertheless, these amounts contribute to
the cumulative overall human body burden of aluminium. In light
of the growing number of toxicological considerations and as a trib-
ute to the public discussion, research in aluminium-free vaccines
should be encouraged and promoted.
4. Aluminium in SCIT
4.1.1. Principles and duration of SCIT
The prevalence of allergic disease is on the rise, it is esti-
mated that almost half the population will develop some form of
allergic disease during the course of their life. Allergen-speciﬁc
immunotherapy commonly consists of administering subcuta-
neous injections using preparations of relevant allergens (Fig. 2),
with the aim to gradually desensitise the allergic patient to the
causative allergen. This may  be achieved through the gradual
release of natural/modiﬁed allergen extracts using a depot medi-
ator (e.g. aluminium salts). By doing so, the natural course of
the disease may  be altered, being shown to redirect the immune
response toward a Th1 immunoglobulin-type G proﬁle and away
from a predominant Th2 immunoglobulin-type E proﬁle which is
linked to the causative symptoms of allergy.
There are various regimens for SCIT treatment (Table 1) [55].
Usually, a phase of titration of the dose upwards is followed by a
maintenance phase at a ﬁxed dose. Some preparations allow for
application intervals of up to 8 weeks, monthly injections are the
recommended and customary practice.
4144 M.F. Kramer, M.D. Heath / Vaccine 32 (2014) 4140–4148
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Table 2
Long-term SCIT courses can signiﬁcantly increase patient exposure to aluminium.
Product type Aluminium allergy
SCIT treatment [61,62]
Infectious disease
vaccine (hepatitis B)
[52]
Adjuvant Aluminium oxyhydroxide
Number of doses per
course
36 3
Al  content per dose
(mg)
1.13 0.25ig. 2. Process ﬂow outlining allergen-adjuvant preparation for immunotherapy
55].
For inhalant allergies, the speciﬁed therapy duration is 3 years
ith up to 5 years for house dust mite allergies [55]. SCIT is usually
ecommended for a duration of 5 years for hymenoptera venom
llergies, whereas life-long monthly therapy may  be given to sub-
roups of patients who have an increased risk of more severe
naphylactic reactions. These sub-groups may  have co-morbidities,
r be prone to increased exposure (e.g. Bee-keepers) [56].
For a typical 3-year therapy, which would usually consist of,
pproximately 16 up-titration injections followed by monthly
njections for a duration of 3 years, a patient will receive over 50
njections within this time-frame [57–59].
Five years of therapy as part of a house dust mite SCIT or
ymenoptera venom allergy, >70 injections are administered in
otal [58]. Taking into account the subgroup of risk patients in
ymenoptera venom allergy, the number of injections of this life-
ong immunotherapy rises inﬁnitely.
Unlike the aforementioned vaccines, the manufacturers of
CIT products are not required to specify the amount of alu-
inium in their SmPCs (summary of product characteristics) or
Is (package leaﬂets). This is, however, in accordance to the Ger-
an  legislation = §  11 Arzneimittelgesetz (AMG). In Europe, 1.25 mg
luminium per injection is considered as the maximum value per-
itted [60]. The accumulative amount of aluminium during typical
ong-course SCIT is summarised in Table 2.
Upon subcutaneous injection, a local reaction forms once the
ntigen-adjuvant preparation comes into contact with the intersti-
ial ﬂuid (tissue space) and plasma. The majority of the adjuvant will
emain in this vicinity for a number of hours, if not days. Dissolution
f particulate aluminium will then occur, partly driven through a
olubility/pH gradient. As more Al3+(aq) evolves it then becomes
vailable for binding by soluble ligands (e.g. transferrin and other
roteins or ligands), thus accelerating the dissolution process [46].The in vivo clearing of aluminium adjuvants has been studied in
ome detail using a radioactive isotope of aluminium (26Al) admin-
stered in rabbits [63]. Mass spectrometry monitored the fate of
able 1
eﬁnitions of sub-cutaneous allergy immunotherapy [55].
Short-term therapy
Approximately four to seven injections prior to the start of seasonal
symptoms (e.g. hay fever).
Pre-seasonal therapy
Weekly injections are administered during a titration phase followed by
monthly maintenance doses, prior to a pollen season.
Perennial therapy
Up to 16 weekly injections (titration phase) followed by monthly
maintenance doses; reduction of the maintenance dose during the
symptom season, if applicable.Cumulative Al dose
(mg)
40.68 0.75
the administered isotope for a period of 28 days. Approximately
1 h after injection, aluminium could be detected in the blood and
remained steady for 28 days, however represented only a small
fraction of the total aluminium dose administered. Urine samples
monitored a 6% cumulative amount of aluminium eliminated in
urine after 28 days, which was still being excreted. It must be
stressed that neither such test will provide an accurate indica-
tion of the total systemic aluminium body burden of an individual
and where it can be found in the body. However, in the same
study the concentration of aluminium was  approximately three
times greater in tissues with the following distribution pattern:
kidney > spleen > liver > heart > lymph node > brain.
As described in Exley [59], “A single injection of 1 mg  of aluminium
adjuvant will add 1 mg  of aluminium to the body burden but this mil-
ligram of aluminium will distribute throughout the body according
to myriad different inﬂuences beginning with those occurring at the
injection site”. While aluminium is released from the injection site
and can be excreted, it clearly has the propensity to form small focal
accumulations in body tissues (including the brain) which can arise
and slowly build over the life-time of an individual.
4.1.2. Aluminium salts: a stimulator of the Th2 immune response
The efﬁcacy of aluminium compounds as adjuvants is undis-
puted, and similarly to vaccines they have been reportedly used
in SCIT since 1937 [52]. The current guideline of German Allergy
Societies classiﬁes aluminium compounds as depot mediators [55].
Other commercial depot mediators used in SCIT are calcium phos-
phate and l-tyrosine. Although the gradual release explanation is
inadequate to explain aluminium’s adjuvant potential, the physi-
cal adsorption of antigen onto the adjuvant is still considered to
be a very important mechanism. Particularly in SCIT where slower
release of allergens from the injection site (thereby increasing the
duration of antigen presentation) is pivotal in improving tolerabil-
ity of the allergens [64].
However, aluminium adjuvants have been consistently demon-
strated to induce IgE [44,46–50] which is clearly an unwanted
and potentially adverse effect in any IgE-mediated disease, such
as allergy. More recent mode-of-action studies have uncovered
some aspects of how aluminium promotes a Th-2 response, but
the precise role(s) of Th2-cytokines is not fully understood [44].
However, it appears that some this response may be mediated and
signalled through a number of relevant interleukin pathways [44].
Since aluminium in SCIT is marketed and described as a depot
adjuvant – a suitable depot carrier should support the immuno-
genic effect of speciﬁc immunotherapy without causing side effects.
Aluminium salts have known side effects listed in the SmPCs, there-
fore physician–patient discussions form paramount importance
in order to ascertain relevant risks. The incidence of persisting
granulomas is reported to be 0.5–6% per hypersensitised patient,
with the injection method being emphasised as a major factor
affecting the frequency of the development of such granulomas
[4]. Case reports describe local reactions, triggered by aluminium
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ompounds such as urticaria, subcutaneous sarcoidosis, progres-
ive circumscribed sclerosis, formation of subcutaneous nodules
nd cutaneous–subcutaneous pseudolymphomas [4,6].
.1.3. Aluminium accumulation in SCIT
Due to the evidence of the chronic toxicity of aluminium
escribed earlier, the discussion of potential safety concerns in SCIT
s not new [59,65]. The risk–beneﬁt assessments of the national
nd international authorities have remained positive over the last
umber of years. This topic was addressed in detail in 2010 by the
uropean Medicines Agency as part of the “CHMP Safety Working
arty response to the PDCO regarding Aluminium Hydroxide contained
n Allergen Products” [65]:
The Paediatric Committee (PDCO) of the European Medicines
gency (EMA) requested the EMA’s Committee for Medical Prod-
cts for Human use (CHMP) to provide a statement on the
luminium exposure with SCIT. The CHMP presented calculations
n the annual cumulative aluminium dose applied in SCIT—for
dults and children. Calculations were based on three scenarios:
.14 mg,  0.5 mg  and 0.15 mg  aluminium per dose applied. The
bsorption rate was assumed to be 100% (cf. above). Six weeks
ere taken as a basis for application intervals during maintenance
herapy. Thus, the authors calculated 9.12 mg,  4 mg  and 1.2 mg  alu-
inium, respectively, as cumulative absorbed annual dose in SCIT.
To compare the amounts of aluminium applied in SCIT, the
HMP’s response to the PDCO indicated the “real dietary intake
EU)” and the “safe oral dietary intake (TWI)”,  respectively, for
dults (65 kg) and for children (20 kg), with the statements of
he EFSA and the WHO  being used as the basis of the data—cf.
bove. The gastrointestinal absorption rate was  based on the gen-
rally accepted range of 0.1–0.3%. Accordingly, the “real dietary
ntake” adds up to an annually absorbed amount of 0.7–15.4 mg
nd 0.73–7.2 mg  in adults and children, respectively, and there-
ore clearly exceeds, particularly in children, the “safe oral dietary
ntake (TWI)” (3.3–10.1 mg  and 1.0–3.1 mg  in adults and children,
espectively). This conﬁrms the assumptions made by the EFSA and
he WHO  that the established thresholds are regularly exceeded, in
articular in children—cf. above.
In addition, the CHMP based its assessment of chronic alu-
inium toxicity on pharmacovigilance databases (reports of
erious and non-serious adverse events from the register of spon-
aneous reports or from clinical studies) from Germany from 1988
o 2008 (7638 reactions were analysed). Due to the low number
f potential aluminium-associated side effects reported (except for
he known granulomas), the CHMP arrived at the conclusion that
here are no safety concerns. To what extent such a database is suit-
ble to detect associations between SCIT and the development of
iseases, which could have a latency period, remains to be seen.
In their conclusion, the Safety Working Party to the CHMP places
he cumulative aluminium dose of 12 mg  aluminium absorbed
rom a 3-year SCIT (0.5 mg  per injection, 6-week interval = 4 mg
er year × 3 years of therapy) in the context of an adult’s lifelong
umulative dose of 165–505 mg  as “safe oral dietary intake (TWI)”.
hus, the contribution of such an SCIT to the lifelong cumulative
otal dose is calculated as being fewer than 10%. In connection
ith the estimation on the basis of the side effects database, the
HMP draws the conclusion that there is no risk from aluminium in
CIT [65].
.1.4. The underlying assumptions under close scrutinisationIt is general practice in toxicology to consider maximal values
within a licensed indication) of the substance in question. The
nal assessment of the CHMP does not seem to be based on a
imilar rationale and it ignored up-titration period(s) completely.ne 32 (2014) 4140–4148 4145
If 1.14 mg  (top aluminium-adjuvant dose) is considered and
6-week intervals, then the human body burden of aluminium
totals 27.36 mg (1.14 mg  × 8 × 3 years). If the maintenance dose
were based on monthly (cf. above) instead of the 6-week intervals,
this amounts to 41.04 mg  (1.14 mg  × 12 × 3 years) and still would
not include up-titration. Over the course of their lives, many aller-
gic patients will receive treatments for several allergens—some
lifelong (cf. above). The cumulative dose of aluminium from
immunotherapy used as basis by the CHMP does not appear to
reﬂect the amount of exposure a patient will receive in practice.
In addition to this, it was compared to dietary intake (i.e. the
immunotherapy cumulative dose being <10% of this) – a route of
administration with a totally different adsorption rate. This is not
only misleading but a fundamental mistake.
In January 2014 the Paul-Ehrlich-Institut (PEI) published its
opinion regarding aluminium in SCIT “Sicherheitsbewertung von
Aluminium in Therapieallergenen” [66]. Within this document, the
German regulatory authority essentially repeats conclusions drawn
from the CHMP in 2010 [65]. For the general risk assessment of alu-
minium PEI refers to the above-mentioned EFSA statement and a
risk assessment from the German Bundesinstitut für Risikobew-
ertung (BfR) from 2007 [15]. Pharmacovigilance (PhV) databases
were screened from 1986 until 2013 without revealing signals –
though as highlighted above there are doubts about as to the use
of such a database in uncovering relationships between SCIT and
e.g., neurodegenerative diseases having a latency period of many
years. A perceived positive beneﬁt–risk-ratio is reiterated in their
statement.
However, since the potential of accumulation of aluminium in
the body is clearly signiﬁcant in the course of SCIT, companies
themselves indicate in relevant sections of their SmPCs as follows:
“During therapy with AVANZ® preparations, taking aluminium-
containing drugs (e.g. antacids) should be restricted.” [67].
Additionally, “This product contains aluminium (4 mg). The risk
of aluminium accumulation in tissues (CNS, bones) must be taken
into account, in particular in case of renal insufﬁciency. The effects
on the immune system of long-term administration of aluminium
are unknown. As this preparation contains a considerable amount
of aluminium, it is recommended to avoid taking other aluminium-
containing medications (e.g. antacids) concomitantly.” [68].
Furthermore, “Patients with Alzheimer’s disease, Down’s syn-
drome and renal insufﬁciency are theoretically at risk from aluminium
intake, including alum precipitated allergenic extracts” [69].
4.1.5. Aluminium as an antigen
While so far it has not yet been deﬁnitely clariﬁed which form of
aluminium acts as an antigen [70], immune reactions to antigenic
aluminium as a consequence of SCIT is plausible. Such immune
reactions would target aluminium deposits in the human body,
which has the potential to contribute to the onset and progression
of aluminium-induced autoimmune diseases [59].
4.1.6. Alternatives to aluminium
The amount of aluminium in SCIT is a signiﬁcant addition to the
lifelong exposure to the metal in children and adults. Taking this
into account the toxicological considerations, it is not unreason-
able to question the long-term impact this has on human health.
Long-term aluminium adjuvant-based immunotherapy treatment
unquestionably predisposes an individual to a likely set of circum-
stances that could lead to accumulation, toxicity and disease.
According to Good Pharmacovigilance Practices, assessment of
a beneﬁt–risk relation must take into account the severity of the
treated disease (e.g. hay fever), the presence of therapy alternatives,
4146 M.F. Kramer, M.D. Heath / Vaccine 32 (2014) 4140–4148
Table 3
Overview of typical detection methods for measuring aluminium in biological samples [76].
Flame AAS GF-AAS ICP AES ICP-MS
Method description The sample is dissociated
through the application of an
air/acetylene or a nitrous
oxide/acetylene ﬂame.
Atoms will absorb the light
from a cathode lamp and a
detector is used to measure the
concentration(s).
Identical principle to FAAS but
using an electrically heated
graphite tube, or cuvette,
which is heated to a
temperature up to 3000 ◦C to
dissociate the sample.
Uses an inductively-coupled
plasma source to dissociate the
sample, atoms/ions are excited
and their characteristic
wavelength is then measured.
Uses an inductively-coupled
plasma source to dissociate the
sample, atoms/ions are
detected directly as opposed to
measuring their excited
wavelength emission(s).
Detection range 30 ppb 0.25 ppb 1.5–6 ppb 0.1–10 ppt
Strengths Ease of use, sampling speed,
value for money, robust
interface and compact
instrument.
Sensitive detection limit,
moderate cost, compact
instrument with low risk of
spectral interferences
Ease of use, expensive but
cost-effective in relation to
multi-element sampling and
screening ability. Solid and
organic samples, low-risk of
chemical interferences.
Most sensitive detection limit,
expensive but cost-effective in
relation to multi-element
sampling and screening ability,
isotopic measurements, lower
risk of interferences, output is
easy to interpret.
Limitations Least sensitive detection limit,
limited number of elements,
Higher risk of chemical
interferences, element limits,
ility.
Higher risk of spectral
interferences with
Highly skilled
operator/training required,
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pand no screening ability. lack of screening ab
nd to the type of risk assessed. In Germany, licensed and com-
rehensively documented alternative products with other depot
ediators are commercially available for example use of l-tyrosine,
 non-essential amino acid physiologically generated from phenyl-
lanine and fully metabolised with a half-time of 48 h, has been
ell-documented as a commercial alternative for over 40 years
71–73]. Other endogenous and biodegradable adjuvant systems
re researched but difﬁculties in achieving regulatory approval
ithout having extensive mode-of-action and safety studies, mak-
ng it costly and time-consuming to bring market [74]. TLRToll-like
eceptor agonists use in immunotherapy (e.g. MPL/CpG motifs) has
hown some excellent beneﬁts [64]. However, such adjuvants will
ot function as depot mediators. The physical adsorption of anti-
en onto the adjuvant and subsequent ‘slow-release’ of antigen is
onsidered to be a very important mechanism, particularly in SCIT.
n some products, the depot mediator – l-Tyrosine – is used in
ombination with MPL. Here, Tyrosine allows slow release of aller-
ens. While MPL  will drive an appropriate immunological response
Th1), thus enabling a unique ultra-short course therapy for the
llergic patient [75].
In summary, the amount of aluminium applied in SCIT
ill signiﬁcantly contribute to a higher cumulative life dose.
nlike essential prophylactic vaccinations, numerous injections
ith higher proportions of aluminium-adjuvant per injection are
pplied in SCIT. Comparably high amounts of aluminium are admin-
stered, particularly during long-term SCIT for hymenoptera venom
llergies whilst there are aluminium-free products commercially
vailable.
. Aluminium analysis
Aluminium analysis is technologically demanding. The very low
oncentrations and possibility of contamination poses problems.
luminium compounds are of biological signiﬁcance—cf. above. The
tability of these aluminium compounds constitutes an additional
omplicating factor in analysis.
However, several methods are available:
The atomic absorption spectrometry (AAS), and particularly
raphite furnace atomic absorption spectrometry (GF-AAS), are sin-
le element methods with detection thresholds of approximately
 g/L. This method is commonly applied for analysing biolog-
cal samples and aqueous media. However, inductively coupled
lasma–optical emission spectrometry (ICP-OES) now providesmulti-elements and sample
types, detection limits can be
moderate.
expensive, dissolved solids
must be <0.2%.
a more sensitive alternative, able to measure lower concentra-
tions of the metal, especially when using quadrupol (ICP-qMS) or
high-resolution sector ﬁeld ICP-MS (ICP-sf-MS). These devices are
however expensive and of limited availability. Table 3 summarises
the type of analytical methods mentioned above, their detection
range(s), strengths and limitations.
The German Research Foundation (DFG) assembled an indepen-
dent expert group entitled “Analyses in Biological Material”. This
group has published research papers on threshold values and meth-
ods (MAK collection) and are able to advise on how to reasonably
measure, e.g., the aluminium exposure caused by SCIT [77]. There is
currently no generally accepted surrogate parameter which would
reﬂect the cumulative burden to the body posed by aluminium [19].
In summary, aluminium analysis is expensive and highly
demanding although the technology is available to detect trace
amounts of the metal in biological samples. The DFG provides inde-
pendent expertise with the work group “Analyses in biological
material”. It is important to note that blood and serum analysis
of aluminium provide unreliable indications in relation to an indi-
vidual’s body burden of aluminium. There is currently ongoing
work on ways in which to measure aluminium accumulation in
humans via non-invasive means. As previously described, one such
method utilising silica-enriched water has thus far yielded promis-
ing results and has been shown to reduce the human body burden
of aluminium. Currently, this method has been shown to reduce the
body burden of aluminium in Alzheimer’s patients, and release sys-
temic aluminium in urine [26,28]. Its application in other contexts
such as in patients undergoing long-term SCIT treatment could be
similarly applied.
6. Summary
Anthropogenic factors over the past 125 hundred years have
increased human exposure to aluminium, resulting in a burgeoning
body burden of this neurotoxin.
Threshold values for foodstuffs established by authorities are
regularly exceeded and aluminium compounds are regularly used
as adjuvants in vaccinations. In SCIT, aluminium compounds are
employed as adjuvants and depot mediators. Unlike essential
prophylactic vaccinations, numerous injections with signiﬁcantly
higher proportions aluminium per injection are applied during
SCIT. However, regulatory authorities currently set aluminium lim-
its for vaccines per dose, rather than per treatment course.
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Based on the currently available literature, the beneﬁt–risk
elationship of long-term aluminium adjuvant SCIT should be
e-assessed according to Good Pharmacovigilance Practices. Alu-
inium will accumulate in the human body over the life-time of
n individual and undoubtedly has the potential to exert chronic
oxic effects, such as neurotoxicity. Predisposing an individual to
n unnecessary high body burden of aluminium should be avoided
nd could reasonably be considered a cause for triggering the onset
r progression of a number of conditions and disease states men-
ioned in this paper. There is however still a lack of epidemiological
tudies examining the possible relationship between the develop-
ents of such diseases, which may  have a latency period of many
ears after the application of SCIT.
In currently on-going SCIT studies, aluminium accumulation
hould be more accurately measured for the entire treatment
eriod. External expertise as provided by the DFG should be
ollected for planning such bio-monitoring. There is currently on-
oing work, using silica-enriched water, to measure aluminium
ccumulation in humans via non-invasive means and ascertain
ore accurate indications of an individual’s body burden of alu-
inium. This could open up the possibility of providing an effective
eans of measurement in patients undergoing long-term SCIT
reatment, as well as reducing the aluminium body burden.
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